The world's first fully automated synthesis module

CISSPECT DESK-LAB represents a great leap forward for the development of radiopharmaceuticals and personalised drug discovery. Recently, we have developed the world’s first fully automated synthesis module, CISSPECT DESK-LAB, for the synthesis of Pt-195m cisplatin and other platinum compounds

Complex Xe-133 project completed

The source material to produce xenon-133 was available. However, an efficient production process that would meet all the legal requirements and the quality assurance of the end product had yet to be developed.

From HEU to LEU medical isotopes

At the 2014 Nuclear Summit, commitments that were done earlier to phase out high enriched uranium (HEU) based medical isotopes and to only use low enriched uranium (LEU), were once again confirmed. This was an important issue because HEU can be used to produce nuclear weapons.

CISSPECT: using radiolabeled cisplatin in precision medicine

Being able to predict which cancer patient is likely to respond to chemotherapy with cisplatin has not yet been possible. However, a unique research project between NRG|PALLAS, the Netherlands Cancer Institute (NKI) and Amsterdam UMC may bring about some change.